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Abstract
After severe myocardial infarction (MI), heart failure results from ischemia, fibrosis, and remodeling. A promising therapy to
enhance cardiac function and induce therapeutic angiogenesis via a paracrine mechanism in MI is myoblast sheet
transplantation. We hypothesized that in a rat model of MI-induced chronic heart failure, this therapy could be further
improved by overexpression of the antiapoptotic, antifibrotic, and proangiogenic hepatocyte growth factor (HGF) in the
myoblast sheets. We studied the ability of wild type (L6-WT) and human HGF-expressing (L6-HGF) L6 myoblast sheet-
derived paracrine factors to stimulate cardiomyocyte, endothelial cell, or smooth muscle cell migration in culture. Further,
we studied the autocrine effect of hHGF-expression on myoblast gene expression profiles by use of microarray analysis. We
induced MI in Wistar rats by left anterior descending coronary artery (LAD) ligation and allowed heart failure to develop for 4
weeks. Thereafter, we administered L6-WT (n = 15) or L6-HGF (n = 16) myoblast sheet therapy. Control rats (n = 13)
underwent LAD ligation and rethoracotomy without therapy, and five rats underwent a sham operation in both surgeries.
We evaluated cardiac function with echocardiography at 2 and 4 weeks after therapy, and analyzed cardiac angiogenesis
and left ventricular architecture from histological sections at 4 weeks. Paracrine mediators from L6-HGF myoblast sheets
effectively induced migration of cardiac endothelial and smooth muscle cells but not cardiomyocytes. Microarray data
revealed that hHGF-expression modulated myoblast gene expression. In vivo, L6-HGF sheet therapy effectively stimulated
angiogenesis in the infarcted and non-infarcted areas. Both L6-WT and L6-HGF therapies enhanced cardiac function and
inhibited remodeling in a similar fashion. In conclusion, L6-HGF therapy effectively induced angiogenesis in the chronically
failing heart. Cardiac function, however, was not further enhanced by hHGF expression.
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Introduction
The quiescent post-inflammatory scar tissue after myocardial
infarction (MI) impairs cardiac function and restricts ventricular
dilatation. In a chronic situation, the active processes such as
inflammation, cell death and necrosis, proteolytic activity, and
overall tissue response to ischemia have gradually ended, and the
tissue has become fibrotic, quiescent, and dysfunctional. In chronic
heart failure (HF), regeneration of such fibroblast- and collagen-
rich scar tissue depleted of myocytes has proved to be an extensive
task for pharmacological or cellular therapy.
Hepatocyte growth factor (HGF) is a pleiotropic cytokine that
induces mitogenesis, motogenesis, and morphogenesis [1]. In the
heart, acute myocardial infarction [2], ischemia reperfusion injury
[3], and congestive heart failure [4] induce expression of HGF. In
myocardial ischemia, HGF has been suggested to counteract
damage and to mediate a regenerative response [5]. Extensive
research has focused on the beneficial effect of HGF in the acute
early stages of MI; little is known, however, about the role HGF
plays in the chronic stage of HF.
Cell therapy has shown promise as an alternative to heart
transplantation [6]. Furthermore, transplantation of cells such as
myoblasts as epicardially deposited sheets has proven a method of
cell delivery superior to invasive intramyocardial injections [7,8].
We recently showed that the effect of myoblast sheets can be
further enhanced by gene therapy, and that after MI, in both acute
and chronic HF their therapeutic effect is mainly mediated
through production of paracrine mediators [9,10]. Moreover, our
results showed that preventing Bcl-2-dependent cell death can
prolong and intensify this production of paracrine effectors from
the sheets. We also identified the factors released from the sheets
and demonstrated that their prolonged production induced
angiogenesis in the ischemic myocardium, inhibited fibrosis,
reduced ventricular dilation, and enhanced cardiac function [9].
We demonstrated that the Bcl-2-expressing myoblast sheets
secreted increased amounts of vascular endothelial growth factor
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(VEGF) and placental growth factor (PlGF) than did the wild type
sheets, and that the angiogenic responses stimulated by myoblast
sheets were mediated via the Flk1/Flt1 signaling pathway [9,10].
In addition to the VEGF family of cytokines, HGF has been
demonstrated after MI to reduce fibrosis and ventricular
remodeling [5], and to enhance angiogenesis [11]. Intriguingly,
these are the same characteristics as were identified to be the
important therapeutic components of myoblast sheet therapy [9].
Such common characteristic mechanisms suggested to us that
synergism could exist between myoblast sheets and hgf gene
therapy in treatment of HF.
In this study, our aim was to evaluate the therapeutic value of
HGF production from epicardially deposited myoblast sheets in
chronic HF. We hypothesized that enhancing the production of
HGF from myoblast sheets would induce a synergistic therapeutic
effect between the overexpressed HGF and the other cytokines,
such as VEGF and PlGF, released from myoblast sheets.
Moreover, HGF therapy might help reduce remodeling and
fibrosis as well as increase blood flow to improve graft survival and
functionality.
Materials and Methods
Cell culture and sheets
Myoblast cell culturing and sheet fabrication followed the
method previously described [9]. The L6 rat skeletal myoblast cell
line came from the American Type Culture Collection (CRL-
1458, Manassas, VA) with cells at passages 5 to 15 used for
experiments. We engineered myoblast cell sheets by plating 66106
myoblasts on thermoreactive cell culture dishes (CellSeed, Tokyo,
Japan) for 16 hours. Intact myoblast sheets detached spontane-
ously from culture dishes at room temperature and were harvested
for transplantation. To study the effect of paracrine mediators
secreted by myoblast sheets, we washed the sheets thoroughly with
serum free medium, incubated the sheets in that medium for
24 hours, and collected the conditioned medium for experiments.
To establish cultures that contain all major cell types of the
myocardium, hearts of fetal Wistar rats (E17.5) were excised and
underwent mincing and enzymatic digestion with trypsin (Sigma-
Aldrich, Saint Louis, MO, USA) and collagenase IV (Worthington
Biomedical, Lakewood, NJ). After a 30-minute enzyme digestion
with shaking in a water bath at 37uC, the supernatant with cells
was collected, and the remaining minced tissue was subjected to
another digestion. We repeated this cycle four times until all tissue
was digested. After digestion, we plated the collected supernatants
in DMEM containing 10% fetal bovine serum, 5% horse serum,
and antibiotics to 24-well cell culture dishes pretreated with 0.2%
gelatin (Sigma-Aldrich) to promote cell adherence.
To establish cultures of cardiac fibroblasts, the myocardial cell
suspensions after enzymatic digestion were plated for 90 minutes
on culture dishes to allow attachment of non-myocyte cells. After
this incubation, the non-adhered cell population was removed.
The cultures were extensively washed to ascertain removal of
myocytes from the culture. We then passaged this early-adherent
cell population 6 times to allow overgrowth and enrichment of
cardiac fibroblasts. We then plated these cells to 24-well plates for
migration experiments or to 96-well plates for the fibrosis assay.
hHGF transfection and verification of overexpression
We transfected the L6 myoblasts for 24 hours in the presence of
pBabepuro retroviral vector and 8 mg/ml polybrene (Sigma-
Aldrich) to create a cell line with constitutive overexpression of
human hgf. The vector came from Biomedicum Genomics,
Helsinki, Finland. We selected the transfected cells with incubation
in growth medium containing 2 mg/ml puromycin for 48 hours.
To verify the success of the transfection, we performed in situ
hybridization of the human hgf mRNA in L6 myoblasts using the
Ventana Discovery Automate (Ventana Medical Systems Inc,
Tuczon, AZ, USA). We used the antisense primer sequence
59-ATTTAGGTGACACTATACACAAGCAATCCAGAGGTA-
CGC-39 to detect hHGF mRNA and sense primer sequence 59-
TAATACGACTCACTATAGGCCTCGGCTGGCCATCGG-
G-39 as the control sequence. For detection of secreted hHGF
from the L6 myoblast sheet culture medium, we used the human
HGF Duoset ELISA kit according to the manufacturer’s protocol
(R&D Systems, Minneapolis, MN).
Analysis of cardiac cell migration
After plating, we incubated the cardiac cell cultures for 48 hours
to allow proper attachment and changed the medium to serum free
for a period of 24 hours. After serum deprivation, we washed the
cultures and scratch-wounded them with a pipette tip. To determine
the ability of myoblast sheet-derived paracrine factors and
transfected hgf to promote migration of cardiac cells, we substituted
the serum free DMEM with 24-hour conditioned medium derived
from L6-WT or L6-HGF myoblast sheets. 24 hours later, we fixed
the cultures with 4% paraformaldehyde and perfused the cells with
Triton-X. We used immunofluorescence staining for von Will-
ebrand factor (vWF, rabbit polyclonal, Millipore, Billerica, MA,
USA) and alfa-smooth muscle actin (SMA, mouse monoclonal,
DAKO Cytomation, Glostrup, Denmark) to identify and evaluate
migrating endothelial and smooth muscle cells. Secondary antibod-
ies were anti-mouse Alexa Fluor 488 and anti-donkey Alexa fluor
596 (Molecular Probes, Eugene, OR). We acquired imuunofluor-
escence images of the denuded area with a Olympus IX81
microscope, DP30BW camera, and Cell F 2.7 software (Olympus,
Tokyo, Japan). We evaluated the number of vWF- and SMA-
positive cells migrating into the denuded area with Photoshop 7.0
(Adobe Systems Inc., Delaware, CA). We acquired phase contrast
images from the cardiac fibroblast cultures and evaluated their
migration with Photoshop 7.0.
Analysis of ventricle dilatation
We analyzed the dilation of the left and right ventricles from
histological sections to accurately determine whether myoblast
sheets can prevent MI-induced remodeling and whether hgf gene
therapy can augment the anti-remodeling effect. We used ImageJ
software (U. S. National Institutes of Health, Bethesda, MD,
http://imagej.nih.gov/ij) to determine the circumference of the
ventricles from hematoxylin/eosin-stained paraffin-embedded
sections. Papillary muscles were omitted from the analysis.
Animals
We operated on 58 Wistar rats (250–400 g). Of these, 49
(84.5%) survived both surgeries and were randomly divided into
four groups: the control group underwent left anterior descending
coronary artery (LAD) ligation and re-thoracotomy (n= 13), the
L6 wild type group (L6-WT) underwent LAD ligation and sheet
transplantation (n= 15), the hgf gene therapy group (L6-HGF)
underwent LAD ligation and sheet transplantation (n= 16), and
the sham operation group (n= 5) underwent thoracotomy twice.
We induced MI by LAD ligation as described previously [12]. We
intubated the animals and maintained respiration with a ventilator
during surgery. We exteriorized the heart rapidly through a left
thoracotomy and pericardiotomy and ligated the LAD 3 mm from
its origin. After ligation, we returned the heart to its normal
position, and covered it with pericardium to avoid adhesion to the
lung and to the chest wall.
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Four weeks after ligation of the LAD, all animals underwent re-
thoracotomy. For animals in L6-WT and L6-HGF groups, two
myoblast sheets each were transplanted on to the left ventricular
anterior wall. Thus, every animal in these groups was grafted with
a total of 1.26107 cells. All animals were euthanized at 4 weeks
after the second surgery.
After the surgery, we antagonized anesthesia with atipamezole
hydrochloride (1.0 mg/kg s.c., AntisedanH, Orion Pharma Inc,
Turku, Finland) and administered buprenorphine hydrocholoride
(0.05 mg/kg sc, TemgesicH, Reckitt and Colman Ltd, Hull, UK)
for post-operative analgesia. Experimental procedures were
conducted according to the US National Institutes of Health
Guide for the Care and Use of Laboratory Animals, and were
approved by the ethics committee of the HUS/Meilahti Hospital
Department of Surgery (permit numbers: ESLH-2008-05359/
Ym-23, STH420A and ESLH-2008-10408/Ym-23, STH991A).
Echocardiography
All animals underwent echocardiography under anesthesia one
day before the first surgery (baseline) as well as 2 weeks and 4
weeks after the second surgery. The echocardiographic measure-
ments were performed with a 7.5 MHz transducer (MyLabH25,
Esaote SpA, Genoa, Italy). We measured anterior and posterior
wall thickness in the diastolic phase (AWTd, PWTd), and left
ventricular diameter in both the diastolic (LVDd) and systolic
(LVDs) phases in the short-axis right parasternal projection just
below the mitral valves. Data was collected from three systolic
cycles and averaged. We used LVDd and LVDs to calculate left
ventricular fraction shortening (LVFS) and ejection fraction
(LVEF) by the following formulas:
LVFS %ð Þ~ LVDd{LVDsð Þ=LVDd
LVEF %ð Þ~ LVDd3{LVDs3 =LVDd3
Histology and immunostaining
Four weeks after the second surgery, and after assessment of
cardiac function, all rats were euthanized. We excised the heart
and cut it into four equal transverse parts. The two middle parts
were fixed in 4% neutral-buffered formalin for 48 hours,
embedded in paraffin, and cut into 4-mm-thick sections for
histology and immunostaining.
We performed immunohistochemistry with a Ventana Discov-
ery Automate (Ventana). Cell proliferation was evaluated by use of
anti-Ki67 antibody (RM-9106, Labvision Inc, Fremont, CA). The
sections stained for Ki67 proliferation-associated antigen were
double-stained for myocytes with an anti-tropomyosin antibody
(MS-1256, Labvision Inc). We analyzed six fields from a single
section (two images from the infarct area, border area, and remote
area). To analyze capillaries and arteries in the myocardium, we
stained endothelial cells with a primary antibody for vWF and
SMA and secondary fluorescent antibody (AlexaFluor 488 and
596). The specificity of the anti-vWF antibody for endothelial cells
was proved against staining and signal co-localization with anti-
PECAM-1 antibody (M-20, Santa Cruz Biotechnology, Santa
Cruz, CA). We acquired images by fluorescent microscopy
(Olympus). We evaluated the proportion of positive cells with
ImageJ software.
Amount of fibrosis was evaluated from Sirius Red-stained
paraffin-embedded sections. The Sirius Red area was divided by
the whole section area to acquire a relative count of cardiac
fibrosis. For analysis, we used scanned images of stained tissue
sections and evaluated fibrotic area with Photoshop 7.0 (Adobe
Systems Inc.).
In vitro fibrosis and apoptosis assays
To study whether paracrine factors derived from L6-HGF
myoblasts can inhibit collagen deposition, such as in the case of
acute MI, or degrade collagen already deposited by fibroblasts as
in chronic MI, we employed an in vitro fibrosis model. To this end,
we cultured human dermal fibroblasts (ATCC, CRL-2088) or rat
cardiac fibroblasts in DMEM containing 10% FBS, as detailed
above, to confluency. L-ascorbic acid 2-phosphate (50 mg/ml,
Sigma-Aldrich) was used to induce collagen deposition while
untreated wells served as baseline. To test the ability of hHGF to
inhibit collagen deposition in these cultures, we treated them with
standard culture medium (control) or L6-HGF conditioned
medium. Medium was changed every 2 days. At 7 days, the
cultures were fixed using 10% formalin, and were washed with
PBS. Deposited collagen was stained with Sirius Red-saturated in
picric acid solution (Sigma-Aldrich). Cultures were then washed
thoroughly with 0.5% acetic acid to remove any unbound dye.
Collagen-bound Sirius Red was dissolved in 0.1 M NaOH and the
amount of collagen was determined by measuring optical density
at 540 nm. For the collagen degradation assay (mimicking an
already formed fibrotic scar), collagen was allowed to accumulate
for 7 days (baseline). Ascorbic acid was then removed from
cultures and incubation was continued with control or with L6-
HGF conditioned medium for another 7 days. Amount of collagen
was then quantitated as described above.
To evaluate whether the hHGF secreted by the myoblasts could
inhibit myoblast apoptosis in an autocrine manner and thus
prolong the duration of therapy, we plated 10,000 myoblasts per
well on a 96-well plate, allowed the cells to adhere for 24 hours.
We then treated the cells with staurosporine to induce apoptosis
for another 24 hours. Myoblast viability was quantitated by the
amount of formazan dye converted from MTT by mitochondria.
We dissolved the formazan dye in DMSO and measured optical
density at 540 nm using a reference wavelength of 620 nm.
Statistical analysis
All data are presented as mean 6 SEM. Differences between
groups were compared with ANOVA followed by a Bonferroni
post test. Statistical analysis was with Graph Pad Prism 4.0
(GraphPad Software Inc., San Diego, CA).
Analysis of gene expression
To study the effect of constitutive hHGF expression on the
phenotype of the donor cells, we determined the whole genome
gene expression profiles of wild type and hHGF-transfected
myoblasts as monolayers or sheets. We isolated total RNA with
Trizol reagent, following the manufacturers’ protocol. Further
sample processing and hybridization to the Affymetrix GeneChip
Rat Genome 230 2.0 chip (Affymetrix, Santa Clara, CA) was by
Biomedicum Genomics, University of Helsinki (http://www.
biomedicumgenomics.fi). All data are complient with the Minu-
mum Information about a Microarray Experiment (MIAME)
giudelines (http://www.mged.org/Workgroups/MIAME/miame.
html), and the raw and normalized data are deposited in the
National Center for Biotechnology Information Gene Expression
Omnibus (NCBI, GEO, http://www.ncbi.nlm.nih.gov/geo/,
series accession number GSE25752) database. Data were
normalized to median with the RMA algorithm.
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Results
hHGF transfection and functionality
We used in situ hybridization to demonstrate the efficacy of
hHGF transfection. In L6-HGF cells the expression of hHGF was
clearly evident as compared to no detectable reactivity for hHGF
mRNA in L6-WT myoblasts (Figure 1A and B).
We then evaluated the amount of hHGF protein secreted into
the culture medium from the L6-HGF myoblast sheets. These
sheets produced 61.366.7 ng/ml during an 24-hour incubation
period whereas no hHGF was detectable in the L6-WT culture
medium (Figure 1C).
To ascertain that the hHGF produced by the myoblast sheets
was active on primary cells isolated from rat myocardium, we
determined by a scratch-wound assay the ability and selectivity of
myoblast-secreted hHGF to induce cell migration in these cultures
containing cardiomyocytes, endothelial cells, smooth muscle cells,
and fibroblasts. To distinguish between cardiac myocyte, smooth
muscle cell, and endothelial migration, the cultures were stained
for tropomyosin, SMA, and vWF respectively at the end of the
Figure 1. Characterization of hHGF transfection. (A) Phase contrast images representing morphology of wild type (L6-WT) or hHGF-expressing
(L6-HGF) rat L6 myoblasts (B). hHGF mRNA undetectable in L6-WT myoblasts by in situ hybridization, whereas in the retrovirus-tranfected L6-HGF
myoblasts, its expression was evident. Images in A and B are from different locations. (C) hHGF secreted by L6-WT and L6-HGF myoblast sheets into
the culture medium in 24 hours was determined by ELISA. hHGF was undetectable from L6-WT myoblast sheets, whereas abundant secretion was
detectable from L6-HGF myoblast sheets.
doi:10.1371/journal.pone.0019161.g001
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experiment. Wounds treated for 24 hours with L6-HGF sheet-
conditioned medium showed a significant induction of SMA-
positive cell migration with 74.564.1 cells as compared to
49.563.0 (p,0.05) cells in the L6-WT-conditioned medium-
treated, or to 33.865.3 (p,0.01) migrating cells in untreated
control wounds (Figure 2A). In this assay, recombinant hHGF
(100 ng/ml) served as the positive control, and it induced
migration of 91.568.9 (p,0.001 for control, p,0.01 for L6-
WT) SMA-positive cells. Analysis of migration of the vWF-positive
cells revealed that the paracrine mediators from L6-HGF myoblast
sheets induced a significantly higher number (21.862.1) of cells in
the denuded area as compared to 7.561.6 (p,0.01) for the control
group, or 14.061.6 (p,0.05) for the L6-WT group. With rhHGF
(100 ng/ml), as the control stimulus, the migration induced was
27.361.9 cells (p,0.001 for control, p,0.01 for L6-WT)
(Figure 2A). We also evaluated the effect of conditioned medium
from L6-WT and L6-HGF sheets, with rhHGF again as the
positive control on migration of cardiac myocytes staining positive
for tropomyosin. In contrast to the effects on migration of SMA-
positive smooth muscle and vWF-positive endothelial cells we
observed no effect on cardiomyocyte migration of the conditioned
media or rhHGF. In the untreated control cultures, we counted
7.363.2 cells in the denuded area; the corresponding figure for
L6-WT was 6.962.6, for L6-HGF 8.063.9, and for rhHGF
5.563.0. We found no difference in cardiac fibroblast migration
between the study groups (Figure 2B).
Cardiac function
At 4 weeks after ligation of LAD and AMI, we used
echocardiography to determine the baseline cardiac function.
Subsequent echocardiography measurements were then conduct-
ed at 2-week and 4-week time-points after the second surgery and
administration of the myoblast sheet therapy to evaluate the effect
of L6-WT and L6-HGF therapies on cardiac function. At baseline,
a 61 to 63% decline in ejection fraction as compared to the non-
infarcted sham group was evident in all LAD-ligated groups
(EF %: control 34.5661.67; L6-WT 32.9162.38; L6-HGF
34.8062.19) indicating development of significant heart failure.
Two weeks after administration of therapy, we found no
differences in ejection fractions between myoblast sheet treatments
and the heart failure control group. At 4 weeks, however, the
ejection fraction of the control group showed a significant decline
against baseline (27.061.56, p,0.05 at 4 weeks), while in both the
L6-WT (32.6861.89) and L6-HGF (32.2461.14) myoblast sheet-
treated groups, no such further deterioration of cardiac function
was observable and cardiac function was significantly better in
both groups as compared to control group (p,0.05 for L6-WT
and L6-HGF, Table 1).
Moreover, L6-WT and L6-HGF sheet therapies sustained the
systolic and diastolic cardiac function by inhibiting left ventricular
dilation. At both 2- and 4-week time-points, the L6-WT group had
significantly lower LVDs (8.8060.22 mm, 9.3760.18, p,0.05 at
2 weeks, p,0.01 at 4 weeks) and LVDd (10.0660.17 mm,
10.7160.14, p,0.05 at 2 weeks, p,0.01 at 4 weeks) values than
did the control group (LVDs 2 week 9.6760.19, 4 week
10.4260.20; LVDd 2 week 10.9560.17, 4 week 11.7660.13).
For the L6-HGF group, LVDd (10.8460.22, p,0.05) and LVDs
(9.4560.25, p,0.05) were significantly lower at 4 weeks than in
the control group (Table 1).
In vivo angiogenesis after myoblast sheet therapy
We have shown earlier that myoblast sheet therapy induces
angiogenesis in chronic heart failure [10]. Now our in vitro results
in myocardial cell migration indicate that hHGF is a selective and
potent inducer of wound healing of endothelial and smooth muscle
cells, suggesting that these cells selectively rather than cardiomy-
ocytes could be the target cells of this therapy. Thus both HGF
and myoblast sheet therapy harbor proangiogenic potential in the
ischemic myocardium [9,11] and could provide a synergistic
therapeutic effect even in the difficult-to-treat setting of chronic
heart failure. Based on this background, we evaluated the ability of
L6-HGF myoblast sheet therapy to induce angiogenesis in vivo in
the rat chronic heart failure model.
In the post-infarct, non-contractile fibrotic scar, MI induced a
strong angiogenic response in the LAD-ligated groups as
compared to the sham-operated group as measured by relative
amount of SMA- and vWF-positive tissue per whole tissue area.
Strikingly, L6-HGF myoblast sheet therapy induced a massive
increase in the already high baseline levels of SMA-positive
(8.3460.47%) and vWF-positive (0.8660.07) tissue as compared
to both control (SMA 4.7960.42, vWF 0.5460.04, p,0.001 bor
both) and L6-WT groups (SMA 6.5360.54, vWF 0.6860.03,
p,0.05 for both), where as L6-WT therapy had a less pronounced
effect (SMA and vWF p,0.05 for control). In the border area of
the failing hearts, L6-HGF sheets again induced a highly
significant increase of 109% and 59% in SMA-positive
(2.6660.29) and vWF-positive (0.7860.05) tissue respectively
(control SMA 1.2760.29, vWF 0.4960.07, p,0.001 for both;
L6-WT SMA 1.6960.15, p,0.01; vWF 0.6460.05, p,0.05). Also
here, L6-WT sheet therapy was significantly less effective in
promoting therapeutic angiogenesis, with evidently minor induc-
tion of both SMA (p,0.05 for control) and vWF-positive tissue
(p,0.05 for control). Furthermore, we found a similar proangio-
genic pattern also in the remote area, where L6-HGF therapy was
highly effective (SMA 0.8260.07, p,0.001 for control and L6-
WT; vWF 0.1860.02, p,0.05 for control) to induce neovascu-
lature (Figures 3A and B).
Analysis of ventricular dilation
For a more detailed analysis of the effect of myoblast sheet
therapy on ventricular remodeling, we evaluated from hematox-
ylin-eosin-stained paraffin-embedded sections left and right
ventricle dilation as well as the thickness of the infarct and septal
walls. In the left ventricle, the L6-WT group showed significantly
less dilation (0.7560.02) than did the controls (0.8760.04,
p,0.05). In L6-HGF group, however, the effect was less evident
(0.8160.03) and failed to reach statistical significance (Figure 4A).
Because, in addition to left ventricular remodeling, MI leads also
to remodeling of the right ventricle, we determined whether
myoblast sheet therapy could inhibit right ventricular remodeling
as well. Interestingly, in the non-infarcted right ventricle, we
observed a similar, an even more noticeable effect, because
L6-WT myoblast sheet therapy mediated a greater anti-remodel-
ing effect (0.6360.02, p,0.001 for control) than did the L6-HGF
therapy (0.7060.02, p,0.001 for control) (Figure 4B). Because
post-MI remodeling is also associated with ventricular wall
thinning [15] and because myoblast sheet therapy induces cell
proliferation in the myocardium [9], we measured infarct and
septal wall thicknesses to reveal the ablity of myoblast sheet
therapy to reduce wall thinning. In both infarct and septal walls,
the L6-HGF group (infarct 0.9060.04, septal 1.9160.08) had
significantly thicker myocardial walls than did the control group
(infarct 0.6860.02, septal 1.5360.06, p,0.05 for both) (Figure 4
C and D).
Analysis of fibrosis
Because HGF and myoblast sheet therapy are antifibrotic after
acute myocardial infarction [5,9], we tested whether L6-HGF
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sheets could reverse or reduce myocardial fibrosis once it already
develops, as in the model of MI-induced chronic heart failure. At 4
weeks after therapy, neither L6-WT nor L6-HGF therapy reduced
the already developed large fibrotic scar (data not shown).
In the in vitro fibrosis assay, human dermal fibroblasts deposited
significantly less collagen in presence of L6-HGF conditioned
medium (optical density: 0.3360.02) than in presence of control
medium (0.5060.02, p,0.001) suggesting that hHGF effectively
inhibits formation of collagen deposits. However, when collagen
was already deposited and the fibrosis inducing factor was absent,
hHGF (0.5160.01) inhibited further accumulation of collagen but
was unable to degrade the already existing deposits (0.5060.004).
In rat cardiac fibroblast cultures, similar results were evident as
collagen deposition was significantly inhibited but degradation was
not induced (Figure S1).
Gene expression in transfected myoblasts
Because HGF is an autocrine mediator of myoblast prolifera-
tion, migration and differentiation [13], and because of the altered
morphology of the L6-HGF myoblasts (Figure 1A), we performed
a full genome microarray analysis to determine whether
constitutive expression of hHGF has autocrine effects on myoblast
gene expression. These changes in gene expression might
modulate myoblast characteristics as donor cells in myoblast sheet
therapy.
The analysis revealed that in L6-HGF myoblast monolayer
cultures, 63 genes were upregulated and 85 genes were
downregulated by more than 2-fold as compared to L6-WT
myoblasts. Differentially expressed genes were associated with
migration (Coro1a, Epha3) and proliferation (Efhd1, Grem1)
(Table S1). hHGF-expression had no effect on expression of
endogenous rat hgf or on other major cytokines/growth factors.
Further, expression of key regulators of apoptosis remained
unchanged, suggesting that hHGF-expression modified neither
survival nor paracrine characteristics of the myoblasts. Gene
ontology (GO) analysis revealed that the upregulated genes were
associated with various biological processes such as wounding and
cell differentiation (Table S2).
Importantly, the differences in gene expression were even
greater between L6-HGF and L6-WT myoblast sheets than
between monolayer cultures. 259 genes were upregulated and 222
downregulated in L6-HGF sheets by over 2-fold as compared to
the L6-WT sheets.
Myoblast apoptosis assay
We evaluated whether hHGF can inhibit myoblast apoptosis in
an autocrine manner. HGF did not protect myoblasts against
apoptosis induced by different concentrations of staurosporine,
suggesting that the L6-HGF sheets do not have a survival benefit
(Figure S2).
Table 1. Echocardiography data.
Baseline
N AWTd PWTd LVDd LVDs FS EF
Sham 5 1.5060.06 1.7060.18 7.5860.15 5.3260.32 30.0063.17 64.8264.73
Control 13 0.5560.02 1.7060.06 10.5660.18 9.2260.14 13.3263.66 34.5661.67
L6-WT 15 0.5960.03 1.6660.09 10.1760.11 8.8960.17 12.6361.08 32.9162.38
L6-HGF 16 0.5560.02 1.5360.06 10.4860.16 9.1360.24 13.5161.18 34.8062.19
2 weeks after 2nd surgery
N AWTd PWTd LVDd LVDs FS EF
Sham 5 1.5660.07 1.9060.08 8.5060.13 5.8060.84 31.6961.55 67.9362.07
Control 13 0.5960.03 1.6760.09 10.9560.17 9.6760.19 12.3861.05 31.6861.86
L6-WT 15 0.6360.03 1.5560.08 10.0660.17 8.8060.22 12.6461.11 33.5362.04
L6-HGF 16 0.5960.03 1.6360.06 10.7560.18 9.2360.23 11.9960.91 32.9361.73
4 weeks after 2nd surgery
N AWTd PWTd LVDd LVDs FS EF
Sham 5 1.7260.07 1.6660.15 7.7260.37 4.9460.19 35.8361.40 73.4461.62
Control 13 0.6560.02 1.7960.07 11.7660.13 10.4260.20 11.4761.18 27.0161.56
L6-WT 15 0.6260.04 1.6560.08 10.7160.14** 9.3760.18** 12.5461.07 32.6861.89*
L6-HGF 16 0.6360.03 1.7760.07 10.8460.22* 9.4560.25* 12.4460.95 32.2461.14*
AWTd, anterior wall thickness; PWTd, posterior wall thickness; LVDd, left ventricular diameter, all in diastolic phase. LVDs, left ventricular diameter in systolic phase, all
units in mm; FS, fraction shortening (%); EF, ejection fraction (%).
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0019161.t001
Figure 2. hHGF functionality. Functionality of secreted hHGF was determined in vitro by a wound-healing assay with isolated cardiac cells. (A) The
number of migrating smooth muscle actin-positive and von Willebrand factor-positive cells into the denuded area 24 hours after wounding was
determined from immunofluorescence images. Recombinant human HGF (rhHGF) served as a positive control. (B) Representative images of
immunofluorescence stains from all the groups. White lines represent the edges of the denuded area. * p,0.05, ** p,0.01, *** p,0.001 as compared
to control; # p,0.05, ## p,0.01 as compared to L6-WT. Data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0019161.g002
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Discussion
Our earlier results demonstrated that the effect of myoblast
sheet transplantation is mediated mainly by growth factor
stimulation of the targeted injured tissue in models of acute and
chronic heart failure. We therefore hypothesized that enhancing
cell sheet properties by introducing overexpression of a gene
associated with angiogenesis, anti-fibrosis, and antiapoptosis could
further promote sheet therapy. We evaluated the impact of
pleiotropic, cardioprotective hgf overexpression in myoblast sheets
on their therapeutic efficacy in a rat model of chronic heart failure.
This chronic model was chosen because patients receiving open-
heart bypass surgery—a procedure during which cell sheet therapy
is possible—may suffer multiple infarctions, and their myocardial
fibrosis and remodeling have already taken place. Therefore, for a
therapy to be effective at this stage, regenerative paracrine
stimulation or replacement of tissue would be essential. Employing
myoblast sheets as the vehicles for the therapeutic stimulatory
paracrine effectors enables higher concentration and longer
duration of therapy than with intramyocardial injections of cells
or cytokines.
In concert with previous findings demonstrating efficacy of
HGF gene therapy [14] promoting myocardial angiogenesis, our
data showed—apparently for the first time—that myoblast sheets’
proangiogenic potential can be enhanced by HGF therapy.
Increased angiogenesis by the hHGF-overexpressing sheets was
evident throughout the myocardium, suggesting that both the
healthy as well as the injured myocardium responds to this
stimulus. Because HGF upregulates VEGF production [15], and
mediates antiapoptotic signaling in myoblasts [16], we wanted to
rule out the possibility that the stimulation of angiogenesis
observed was due to other factors induced by hHGF in the
myoblast sheets in an autocrine manner. To elucidate the effect of
constitutive hHGF expression on the transplanted myoblasts’ gene
expression, we performed microarray analysis. Both gene
expression and the morphology of the myoblast were strongly
altered by constitutive hHGF expression. Microarrays revealed
differences in expression of genes related to cell migration and the
cell cycle. No major changes were observable in expression of
genes associated with apoptosis or paracrine secretion. These data
suggest that hHGF does not alter the paracrine profile of myoblast
sheets and that the effects observed in vivo are due to hHGF alone
or to hHGF-stimulated target tissue responses.
The major mechanism behind the therapeutic action of myoblast
sheet transplantation is paracrine stimulation of the injured
myocardium. Although skeletal myoblasts produce several factors
[17], the majority of these are positive regulators of angiogenesis. In
our study using the rat chronic heart failure model, we
demonstrated that endothelial cell responses to myoblast sheet-
derived paracrine factors are mediated by VEGF-A and PlGF [9].
Induction of VEGF is an early, yet persistant response to MI. In
contrast, HGF is induced in MI only after its acute stage. HGF
exerts its mitogenic, motogenic, and morphogenic actions in a
complimentary and synergistic fashion, yet one distinct from that of
VEGF [18]. Studies in acute MI models have shown the beneficial
functional effect of HGF therapy to be mediated through induction
of angiogenesis [11], reduction of fibrosis [5], and contribution to
recruitment of stem cells from the bone marrow [19] – effects
associated with myocardial regeneration.
Our findings, however, are in direct contrast to findings of
functional improvement after HGF therapy in acute MI models.
This can be attributed to differences in experimental settings. We
previously showed, using this chronic heart failure model, that an
overall enhancement of myoblast sheet functionality and survival
by antiapoptotic Bcl-2 was associated with improved left
ventricular function. The fact that the introduction of a single
cytokine could not reproduce this effect despite its proangiogenic
ability suggests that in this chronic setting, functional improvement
and therapeutic angiogenesis may be specific and separate
components and may thus be uncoupled. Furthermore, our results
imply that enhancing the production of a single paracrine
mediator is not a viable therapy option when designing
modifications of myoblast sheet therapy. The fact that LV
function failed to improve was not associated with inability of
the human HGF to induce motility of rat cardiac cells. In fact,
those factors produced by L6-HGF sheets were superior to ones
produced by L6-WT sheets to promote vWF and SMA-positive
cell, but not fibroblast, migration.
Others have shown HGF to suppress the development of fibrosis
after MI [5]. The ability of HGF to reverse existing fibrosis when it
has developed, weeks after MI, has not been reported. Our data
Figure 3. Analysis of angiogenesis in vivo. At the study end-point,
4 weeks after administration of therapy, the relative area of smooth
muscle actin (SMA) (A) and von Willebrand factor (vWF) (B) –positive
cells in the myocardium were determined from sham-operated, control
(Ctrl), wild type myoblast sheet therapy (L6-WT) groups, and hHGF-
expressing myoblast sheet therapy (L6-HGF) groups. Separate analysis
was done of the infarct, border, and remote areas of the myocardium.
* p,0.05, *** p,0.001 as compared to control group; # p,0.05,
## p,0.01, ### p,0.001 as compared to L6-WT group. Data are
presented as mean 6 SEM.
doi:10.1371/journal.pone.0019161.g003
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suggests that once the infarct scar is fully developed, HGF alone is
insufficient to reduce that scar. In counteracting fibrosis, HGF
promotes extracellular matrix remodeling via upregulation of
proteolytic factors such as matrix metalloprotease 1 [20].
Furthermore, HGF downregulates expression of TGF-B, a key
regulator of fibrosis that promotes matrix deposition by myofi-
broblasts [21]. In the current model, myocardial fibrosis was fully
developed before therapy administration. Expression of acute
profibrotic factors such as TGF-B1 and TGF-B2 had therefore
receded [22]. Although expression of the third TGF-B isoform,
TGF-B3, may be sustained for a longer period, HGF seems to be
unable to modulate already established fibrosis in a manner
providing any functional benefit.
We conclude that, after an MI, HGF supplementation from
myoblast sheets is an effective strategy to enhance angiogenesis in
the chronically failing fibrotic myocardium. In contrast to several
other reports linking myocardial angiogenesis to enhanced cardiac
performance, our data do not support such a direct association.
Supporting Information
Figure S1 Analysis of the antifibrotic effect of hHGF in
vitro. L-ascorbic acid 2-phosphate induced collagen deposition in
control (Ctrl, standard culture medium) cultures as compared to
untreated baseline in human dermal and rat cardiac fibroblasts.
When collagen was induced in presence of hHGF from L6
myoblasts (L6-HGF), deposition was significantly inhibited (upper
panel). When L-ascorbic acid 2-phosphate-induced collagen was
already deposited for 7 days (baseline) and then removed from
culture, L6-HGF paracrine factors inhibited further deposition as
compared to control (standard culture medium) but could not
reduce existing deposits in either dermal or cardiac fibroblasts
(lower panel). *** p,0.001 as compared to control; ###
p,0.001 as compared to baseline.
(EPS)
Figure S2 Evaluation of apoptosis in myoblasts. Wild
type (L6-WT) or hHGF-expressing (L6-HGF) myoblasts were
treated with indicated concentrations of staurosporine for
24 hours to induce apoptosis. hHGF-expression did not signifi-
cantly affect myoblast apoptosis in an autocrine manner.
(EPS)
Table S1 Differential gene expression by hHGF. Ten
most upregulated and downregulated genes in L6-HGF myoblasts
as compared to L6-WT myoblasts in monolayer culture.
(XLSX)
Table S2 Gene ontology (GO) categories. GO groups
significantly associated with the differentially expressed genes in
L6-HGF myoblasts as compared to L6-WT myoblasts.
(XLSX)
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